AbCellera Biologics Inc. (ABCL)
| Market Cap | 2.19B |
| Revenue (ttm) | 443.80M |
| Net Income (ttm) | 210.52M |
| Shares Out | 281.58M |
| EPS (ttm) | 0.64 |
| PE Ratio | 12.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,161,898 |
| Open | 8.05 |
| Previous Close | 7.81 |
| Day's Range | 7.62 - 8.05 |
| 52-Week Range | 7.42 - 55.22 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 38.88 (+400.4%) |
| Earnings Date | n/a |
About ABCL
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is 38.88, which is an increase of 400.39% from the latest price.
News
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
AbCellera Announces Changes to Its Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Changes to Its Board of Directors
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emer...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized for Emergency Use in COVID-19 Patients Under the Age of 12
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
AbCellera Reports Q3 2021 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q3 2021 Business Results
How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%
The consensus price target hints at a 160.5% upside potential for AbCellera Biologics Inc. (ABCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...
AbCellera Announces Virtual Presentations at Investor Conferences in November
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Virtual Presentations at Investor Conferences in November
Why AbCellera Biologics Stock Sank 21.6% in October
The biotech is now down roughly 56% across 2021's trading.
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Go...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for COVI...
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
Why AbCellera Biologics Stock Jumped 19.4% Last Month
Despite last month's gains, the biotech stock is now down roughly 61% year to date.
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a mu...
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SAR...
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to ...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Why AbCellera Biologics Stock Jumped 7% on Wednesday
The company's drug-development technology is starting to attract attention.
AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage ...
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
VANCOUVER, British Columbia & BOSTON--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
Here's Why AbCellera Biologics Stock Gained 10.6% Last Month
Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.
Why AbCellera Biologics Stock Was Up More Than 17% on Friday
The biopharma company's second quarter was better than expected. The future looks pretty bright, too.
AbCellera Reports Q2 2021 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.